InMed Pharmaceuticals Inc. (INM)
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $4.9M
- Net income
- -$8.2M
- Total assets
- $15.6M
- Market cap
- $9.1M
- Gross margin
- 34.5%
- Operating margin
- -95.3%
- Net margin
- -165.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.9M
- Cost of revenue
- $3.2M
- Gross profit
- $1.7M
- Operating expenses
- $9.7M
- Operating income
- -$4.7M
- Net income
- -$8.2M
- EPS (basic)
- $-8.36
- EPS (diluted)
- $-8.36
Balance sheet
- Total assets
- $15.6M
- Current assets
- $12.9M
- Total liabilities
- $2.1M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $13.4M
Cash flow
- Operating cash flow
- -$7.8M
- Investing cash flow
- -$4.5M
- Financing cash flow
- $12.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $9.1M
- EPS (diluted)
- $-8.36
- Shares outstanding
- 6.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 10, 2020
InMed Pharmaceuticals Inc. (INM) Stock Price
- Reported a net loss of $8.2M in FY2025.
- Gross margin of 34.5%, net margin -165.1%.
- Trading 47% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review InMed Pharmaceuticals Inc..
Write a review
News about InMed Pharmaceuticals Inc.
News & sentiment via Polygon.io
InMed Pharmaceuticals Inc.: frequently asked questions
Is InMed Pharmaceuticals Inc. an American company?
InMed Pharmaceuticals Inc. is a US-based company headquartered in Vancouver, A1, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is InMed Pharmaceuticals Inc. headquartered?
InMed Pharmaceuticals Inc. is headquartered in Vancouver, A1, United States.
Is InMed Pharmaceuticals Inc. publicly traded?
Yes — InMed Pharmaceuticals Inc. is a publicly traded company. Its stock trades under the ticker symbol INM on the NASDAQ.
What does InMed Pharmaceuticals Inc. do?
InMed Pharmaceuticals Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
